Clinical Trial News and Research

RSS

Experts in Parkinson's research propose roadmap for drug trials targeting alpha-synuclein

A recently discovered protein, alpha-synuclein, has become one of the most attractive targets for developing new drugs with the potential to slow down or arrest the progression of Parkinson's disease

20 Dec 2018

Ultrasensitive test detects corrupted protein associated with Alzheimer's and CTE

An ultrasensitive test has been developed that detects a corrupted protein associated with Alzheimer's disease and chronic traumatic encephalopathy, a condition found in athletes, military veterans, and others with a history of repetitive brain trauma.

20 Dec 2018

Exercising three times a week can improve brain power in seniors

According to a new study, walking or cycling or participating aerobic exercises at least three times a week can improve brain power among the elderly. Along with this regular healthy diet can also improve brain’s capacities and capabilities says the study. The study titled “Lifestyle and neurocognition in older adults with cognitive impairments: A randomized trial” was published in the latest issue of the journal Neurology.

20 Dec 2018

Advanced stem cell approach could help fight Parkinson's disease

Scientists have taken a key step towards improving an emerging class of treatments for Parkinson's disease.

20 Dec 2018

WU biomedical engineer makes a significant step toward precision medicine

In 2015, then President Barack Obama launched a precision medicine initiative, saying that its promise was "delivering the right treatments, at the right time, every time to the right person.

20 Dec 2018

Potential combination therapy against rare disease of the bone marrow could improve treatment

Myelofibrosis is a severe and very rare hematological disease for which treatment has only been partially effective to date. Its low incidence rate is one of the reasons why effective therapies are still lacking.

19 Dec 2018

SLU researcher aims to eliminate TB with focus on high-risk patients

In a recent paper published in PLOS One, Soumya Chatterjee, M.D., assistant professor of infectious diseases, allergy and immunology at Saint Louis University, presents data to show that a focus on high-risk tuberculosis patients may be the answer to stalled progress in stamping out the illness in the United States.

19 Dec 2018

New therapy for childhood blindness shows 'very promising' results

A new therapy aimed at improving the sight of people with one of the most common forms of childhood blindness, has shown 'very promising' initial results, according to a study involving UCL researchers.

18 Dec 2018

Researchers discover promising new compound against Buruli ulcer

Buruli ulcer - one of the most neglected among the NTDs - is a debilitating and stigmatizing disease. Affecting mainly children in West and Central Africa, the chronic disease results in devastating skin lesions and can lead to permanent disfigurement and long-term disabilities.

18 Dec 2018

Intraocular injection improves vision in a form of congenital retinal blindness

A new treatment for patients with a form of congenital retinal blindness has shown success in improving vision, according to results published today in Nature Medicine led by researchers at the Scheie Eye Institute in the Perelman School of Medicine at the University of Pennsylvania.

18 Dec 2018

CTF along with NTAP and Sage announce first-ever open data portal for neurofibromatosis

The Children's Tumor Foundation, together with the Neurofibromatosis Therapeutic Acceleration Program and Sage Bionetworks, has announced the first-ever open data portal for scientific research results in the field of neurofibromatosis.

17 Dec 2018

Eisai enters into agreement with Eurofarma for its anti-obesity agent lorcaserin

Eisai Co., Ltd. has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride in Brazil to Eurofarma Laboratorios S.A. Under this agreement, Eisai will supply Eurofarma with lorcaserin. Eisai will receive a one-time contractual payment and is eligible for milestone payments for sales in Brazil.

17 Dec 2018

Research offers hope for patients with serious bone marrow cancer

Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

14 Dec 2018

Study highlights need for personalized approach to treat ICU acquired delirium

A population heath study from the Regenstrief Institute and Indiana University Center for Aging Research has determined that halo, did not benefit elective thoracic surgery ICU patients when given prophylactically, with the possible exception of those who have had surgery to remove their esophagus.

14 Dec 2018

New drug shows promise in treating sarcomas

A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

14 Dec 2018

Butantan Institute signs collaboration agreement with MSD to develop dengue vaccines

On Wednesday, December 12, 2018, Brazil's Butantan Institute signed a collaboration agreement with Merck Sharp & Dohme (MSD) to develop dengue vaccines.

12 Dec 2018

Targeting biochemical pathway may lead to new therapies for alleviating symptoms of anxiety disorders

According to some estimates, up to one in three people around the world may experience severe anxiety in their lifetime.

12 Dec 2018

Study could lead to a potential new way of treating sepsis

Australian emergency doctors are at the forefront of a large clinical study to assess how clinicians are treating sepsis.

11 Dec 2018

People who eat red meat have high levels of chemical associated with heart disease, study finds

Researchers have identified another reason to limit red meat consumption: high levels of a gut-generated chemical called trimethylamine N-oxide, that also is linked to heart disease.

11 Dec 2018

Ezogabine treatment reduces motor neuron excitability in ALS patients, study shows

Brian Wainger, MD, PhD, of the Healey Center for ALS at Massachusetts General Hospital presented initial, top-level results of a recently completed phase 2 clinical trial of ezogabine (also called retigabine) on December 9 at the Motor Neurone Disease Association annual meeting in Glasgow, Scotland.

11 Dec 2018

Clinical Trial News and Research

Experts in Parkinson's research propose roadmap for drug trials targeting alpha-synuclein

Ultrasensitive test detects corrupted protein associated with Alzheimer's and CTE

Exercising three times a week can improve brain power in seniors

Advanced stem cell approach could help fight Parkinson's disease

WU biomedical engineer makes a significant step toward precision medicine

Potential combination therapy against rare disease of the bone marrow could improve treatment

SLU researcher aims to eliminate TB with focus on high-risk patients

New therapy for childhood blindness shows 'very promising' results

Researchers discover promising new compound against Buruli ulcer

Intraocular injection improves vision in a form of congenital retinal blindness

CTF along with NTAP and Sage announce first-ever open data portal for neurofibromatosis

Eisai enters into agreement with Eurofarma for its anti-obesity agent lorcaserin

Research offers hope for patients with serious bone marrow cancer

Study highlights need for personalized approach to treat ICU acquired delirium

New drug shows promise in treating sarcomas

Butantan Institute signs collaboration agreement with MSD to develop dengue vaccines

Targeting biochemical pathway may lead to new therapies for alleviating symptoms of anxiety disorders

Study could lead to a potential new way of treating sepsis

People who eat red meat have high levels of chemical associated with heart disease, study finds

Ezogabine treatment reduces motor neuron excitability in ALS patients, study shows

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer